The Klase Lab is interested in the overlapping problems of HIV-1 transcription, HIV-1 neuropathogenesis and substance use disorders.

Ongoing Projects

We are working on:

  • Understanding how prescription benzodiazepines (such as Valium and Xanax) alter chromatin and affect viral gene expression.
  • Studying the role of the HIV-1 Tat protein in neuropathogenesis.
  • Determining how alteration of miRNA expression by the virus may drive neuropathogenesis.
  • Describing the mechanism whereby substances of abuse (such as opioids and benzodiazepines) exacerbate HIV-1 associated neurodegenerative disorders.
  • Studying the immune mechanisms that allow a small fraction of HIV-1 infected individuals to control the virus in the absence of therapy.
  • Developing technologies to improve our understanding of epigenetics and chromatin dynamics in the nucleus.

Klase Lab research: Prescription benzodiazepines activate the latent HIV-1 LTR
Prescription benzodiazepines activate the latent HIV-1 LTR


Klase Lab research: Tat protein and morphine show combined affect in suppressing β-catenin
The Tat protein and morphine show combined affect in suppressing β-catenin, a key neuroprotective factor


Klase Lab research: High resolution imaging of chromatin in three dimensions
High-resolution imaging of chromatin in three dimensions: green – histone H3 methylated at lysine 27, red – the methyltransferase SUV39H1


Klase Lab research: A model for alprazolam alters the chromatin at the integrated HIV-1 LTR through inhibition of RUNX1 and activation of STAT5
A model for alprazolam alters the chromatin at the integrated HIV-1 LTR through inhibition of RUNX1 and activation of STAT5.

 
 Back to Top